Health Enhancement Products (HEPI) has reported that based on observations of ProAlgaZyme (PAZ) activity during tests for inflammation management, Wayne State University School of Medicine professor of pathology Fazlul Sarkar has noted that beneficial properties were exhibited by the natural compound when interacting with pancreatic cancer cells in-vitro.
Reportedly, these preliminary, positive observations have moved Dr Sarkar to consider probing the cancer-related properties of PAZ further. The noted researcher proposed that HEPI immediately authorise a new series of tests to study the potential that PAZ may hold for enhancing the effectiveness of chemotherapy in addressing untreatable cancers.
The company has authorised a new series of tests to determine whether PAZ has the potential to act as a chemo-sensitising agent prior to chemotherapy, as a direct chemotherapy enhancement in combination with other drugs and/or function as a chemoprevention compound that may help ward off the onset of cancer.
The company said that the results of these new cancer-related tests will be known in a few weeks, but the company will not disclose findings until any relevant patent applications are prepared, submitted and accepted.
Dr Sarkar, professor of pathology at the Wayne State University School of Medicine, said: “I observed that PAZ exhibited no measurable toxicity toward human white blood cells in vitro during our tests for inflammation management. In a related inflammation test conducted at the same time, it was observed that PAZ also demonstrated the potential to affect the in-vitro growth of human pancreatic cancer cells.
“These observations have caused us to consider the possibility that PAZ may be able to chemo-sensitise cancer cells so that standard chemotherapy could potentially work better. It’s too compelling a development not to study the properties immediately.”
